interferon beta-1b 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5140 145155-23-3

Description:

MoleculeDescription

Synonyms:

  • interferon beta-1b
  • betaseron
A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS. A possible role for IFNs in prophylaxis or early treatment of COVID-19 has been suggested to compensate for possibly insufficient endogenous IFN production. However, the efficacy and safety of IFNs for treatment or prevention of COVID-19 were not established.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
4 MU P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 23, 1993 FDA BAYER HEALTHCARE PHARMS
Nov. 30, 1995 EMA Bayer AG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1574.90 15.49 581 24953 51724 90551189
Influenza like illness 1157.79 15.49 527 25007 80084 90522829
Injection site erythema 1080.87 15.49 535 24999 97967 90504946
Injection site pain 854.11 15.49 558 24976 173141 90429772
Injection site mass 571.48 15.49 220 25314 21870 90581043
Injection site reaction 552.40 15.49 336 25198 91744 90511169
Injection site bruising 448.20 15.49 241 25293 52066 90550847
Multiple sclerosis 361.29 15.49 170 25364 27670 90575243
Chills 333.82 15.49 285 25249 131696 90471217
Injection site induration 276.84 15.49 106 25428 10362 90592551
Injection site rash 257.54 15.49 129 25405 24044 90578869
Injection site scar 248.37 15.49 60 25474 1197 90601716
Injection site necrosis 232.84 15.49 59 25475 1442 90601471
Gait disturbance 195.38 15.49 299 25235 260197 90342716
Injection site atrophy 175.58 15.49 42 25492 802 90602111
Product dose omission issue 174.19 15.49 302 25232 291385 90311528
Off label use 163.39 15.49 54 25480 1102198 89500715
Injection site abscess 157.55 15.49 43 25491 1411 90601502
Injection site cellulitis 155.63 15.49 43 25491 1478 90601435
Depression 154.96 15.49 292 25242 300309 90302604
Balance disorder 148.55 15.49 159 25375 96921 90505992
Optic neuritis 140.77 15.49 64 25470 9614 90593299
Injection site ulcer 137.96 15.49 33 25501 630 90602283
Injection site discolouration 133.57 15.49 61 25473 9259 90593654
Injection site infection 133.31 15.49 42 25492 2290 90600623
Injection site haematoma 127.34 15.49 54 25480 6868 90596045
Hypoaesthesia 123.64 15.49 273 25261 313937 90288976
Central nervous system lesion 109.06 15.49 57 25477 11589 90591324
Injection site inflammation 102.47 15.49 41 25493 4500 90598413
Injection site swelling 102.24 15.49 104 25430 59735 90543178
Muscular weakness 101.72 15.49 197 25337 206469 90396444
Depressed mood 87.09 15.49 88 25446 50134 90552779
Injection site urticaria 83.59 15.49 56 25478 17955 90584958
Seizure 81.89 15.49 151 25383 152478 90450435
Tremor 80.25 15.49 150 25384 153023 90449890
Joint swelling 79.09 15.49 22 25512 503278 90099635
Glossodynia 74.32 15.49 4 25530 321775 90281138
Abdominal discomfort 72.90 15.49 22 25512 477306 90125607
Fall 69.44 15.49 294 25240 481516 90121397
Rheumatoid arthritis 66.81 15.49 11 25523 362603 90240310
Feeling cold 66.62 15.49 58 25476 27407 90575506
Injection site calcification 65.89 15.49 11 25523 25 90602888
Arthropathy 65.53 15.49 12 25522 366230 90236683
Injection site pruritus 61.72 15.49 76 25458 53758 90549155
Wound 60.98 15.49 7 25527 302973 90299940
Lower respiratory tract infection 58.24 15.49 3 25531 250656 90352257
Paraparesis 57.65 15.49 24 25510 2914 90599999
Pyrexia 56.45 15.49 348 25186 660137 89942776
Wheezing 54.84 15.49 3 25531 238077 90364836
Systemic lupus erythematosus 54.65 15.49 17 25517 361879 90241034
Hemianaesthesia 54.19 15.49 14 25520 370 90602543
Coordination abnormal 53.62 15.49 46 25488 21310 90581603
Toxicity to various agents 52.42 15.49 9 25525 287837 90315076
Injection site irritation 52.24 15.49 28 25506 5987 90596926
Psoriatic arthropathy 52.21 15.49 3 25531 228332 90374581
Injection site haemorrhage 49.78 15.49 50 25484 28268 90574645
Stomatitis 49.12 15.49 9 25525 274689 90328224
Gait inability 48.42 15.49 119 25415 146337 90456576
Diarrhoea 47.01 15.49 124 25410 939066 89663847
Blister 46.36 15.49 8 25526 254990 90347923
Feeling abnormal 46.17 15.49 127 25407 167108 90435805
Acute kidney injury 44.99 15.49 17 25517 320370 90282543
Progressive multiple sclerosis 44.88 15.49 16 25518 1278 90601635
Sensory disturbance 44.50 15.49 36 25498 15377 90587536
Therapeutic product effect decreased 43.80 15.49 12 25522 277559 90325354
Urinary incontinence 43 15.49 53 25481 37513 90565400
Peroneal nerve palsy 42.33 15.49 24 25510 5724 90597189
Injection site scab 42.10 15.49 13 25521 663 90602250
Urinary tract infection 42.01 15.49 184 25350 305448 90297465
Pain in extremity 42.00 15.49 243 25291 450286 90152627
Decreased interest 39.64 15.49 21 25513 4386 90598527
Fatigue 39.62 15.49 497 25037 1153526 89449387
Limb discomfort 39.29 15.49 51 25483 38009 90564904
Intentional product use issue 39.00 15.49 7 25527 216885 90386028
Irritable bowel syndrome 38.84 15.49 6 25528 207442 90395471
Headache 38.37 15.49 391 25143 862355 89740558
Secondary progressive multiple sclerosis 38.22 15.49 15 25519 1564 90601349
Condition aggravated 37.67 15.49 69 25465 595476 90007437
Rash 37.63 15.49 108 25426 795992 89806921
Breast cancer female 37.24 15.49 32 25502 14854 90588059
Neutralising antibodies positive 36.70 15.49 10 25524 326 90602587
Drug interaction 36.64 15.49 16 25518 276437 90326476
Fibromyalgia 36.35 15.49 7 25527 206262 90396651
Peripheral swelling 35.98 15.49 38 25496 413068 90189845
Expanded disability status scale score increased 35.59 15.49 12 25522 811 90602102
Burning sensation 35.54 15.49 64 25470 63388 90539525
Infection 35.40 15.49 30 25504 362064 90240849
Impaired healing 35.34 15.49 11 25523 234188 90368725
Injury 34.14 15.49 7 25527 197342 90405571
Osteoarthritis 33.74 15.49 7 25527 195723 90407190
Anti-interferon antibody positive 33.60 15.49 6 25528 23 90602890
Febrile neutropenia 33.55 15.49 3 25531 158346 90444567
Ill-defined disorder 33.17 15.49 6 25528 184885 90418028
Drug intolerance 32.84 15.49 47 25487 447544 90155369
Memory impairment 32.00 15.49 125 25409 197119 90405794
Asthenia 31.88 15.49 258 25276 533493 90069420
Muscle spasms 31.86 15.49 148 25386 251735 90351178
Swelling 31.75 15.49 43 25491 419015 90183898
Type 2 diabetes mellitus 31.66 15.49 9 25525 203235 90399678
Loss of consciousness 31.52 15.49 99 25435 140139 90462774
Therapeutic product effect incomplete 31.30 15.49 8 25526 193888 90409025
C-reactive protein increased 30.23 15.49 7 25527 181382 90421531
Completed suicide 30.06 15.49 3 25531 145055 90457858
Neutropenia 29.82 15.49 13 25521 224891 90378022
Oedema 29.17 15.49 10 25524 200285 90402628
Decreased appetite 29.17 15.49 38 25496 376502 90226411
Discomfort 28.99 15.49 21 25513 274314 90328599
Paraesthesia 28.71 15.49 143 25391 250183 90352730
Treatment failure 28.71 15.49 26 25508 303902 90299011
Demyelination 27.81 15.49 21 25513 8119 90594794
Liver injury 27.60 15.49 7 25527 170560 90432353
General physical health deterioration 27.33 15.49 36 25498 355079 90247834
Alopecia 27.33 15.49 62 25472 495009 90107904
Trigeminal neuralgia 27.10 15.49 16 25518 4115 90598798
Muscle spasticity 27.02 15.49 41 25493 35281 90567632
Speech disorder 26.84 15.49 47 25487 45538 90557375
Gastrointestinal disorder 26.67 15.49 20 25514 256667 90346246
Ataxia 26.59 15.49 29 25505 18013 90584900
Bursitis 26.57 15.49 3 25531 131651 90471262
Injection site erosion 26.26 15.49 6 25528 93 90602820
Device leakage 26.06 15.49 22 25512 9969 90592944
Product use in unapproved indication 25.97 15.49 34 25500 336202 90266711
Drug hypersensitivity 24.83 15.49 59 25475 463550 90139363
Hyponatraemia 24.68 15.49 4 25530 133534 90469379
Bladder disorder 24.62 15.49 22 25512 10750 90592163
Sinusitis 24.20 15.49 37 25497 343051 90259862
Micturition urgency 23.83 15.49 22 25512 11211 90591702
Injection site nerve damage 23.55 15.49 5 25529 54 90602859
Injection site nodule 23.42 15.49 15 25519 4458 90598455
Pneumonia 23.06 15.49 97 25437 637962 89964951
Hypotension 23.04 15.49 35 25499 325362 90277551
Seizure like phenomena 22.79 15.49 10 25524 1380 90601533
Visual impairment 22.37 15.49 85 25449 132280 90470633
Vision blurred 22.20 15.49 75 25459 110218 90492695
Monoparesis 22.11 15.49 11 25523 2016 90600897
Hypersensitivity 21.93 15.49 61 25473 454616 90148297
Blood cholesterol increased 21.87 15.49 16 25518 207996 90394917
Injection site fibrosis 21.71 15.49 4 25530 19 90602894
Scar 21.40 15.49 24 25510 15371 90587542
Automatic bladder 21.34 15.49 5 25529 87 90602826
Fat necrosis 21.26 15.49 8 25526 744 90602169
Joint range of motion decreased 21.13 15.49 6 25528 135637 90467276
Overdose 21.09 15.49 9 25525 157700 90445213
Dyspnoea 20.88 15.49 154 25380 880801 89722112
Head injury 20.80 15.49 34 25500 31154 90571759
Pulmonary fibrosis 20.37 15.49 3 25531 107500 90495413
Weight increased 20.20 15.49 56 25478 417871 90185042
Thyroid function test abnormal 19.95 15.49 13 25521 3976 90598937
Sleep disorder 19.84 15.49 16 25518 198014 90404899
Lack of injection site rotation 19.61 15.49 8 25526 923 90601990
Decubitus ulcer 19.20 15.49 20 25514 11793 90591120
Lipoatrophy 19.19 15.49 6 25528 319 90602594
Breast cancer 19.16 15.49 45 25489 53716 90549197
Diplegia 19.10 15.49 9 25525 1466 90601447
Injection site injury 19.06 15.49 8 25526 991 90601922
Magnetic resonance imaging abnormal 19.02 15.49 12 25522 3474 90599439
Hemiparesis 18.98 15.49 33 25501 31786 90571127
Diplopia 18.74 15.49 31 25503 28683 90574230
Skin mass 18.64 15.49 16 25518 7414 90595499
Needle fatigue 18.53 15.49 5 25529 157 90602756
Arthralgia 18.48 15.49 136 25398 778386 89824527
Accident at home 18.32 15.49 5 25529 164 90602749
Hypokalaemia 18.32 15.49 7 25527 131109 90471804
Quadriplegia 18.30 15.49 10 25524 2221 90600692
Therapy non-responder 17.96 15.49 8 25526 136696 90466217
Neutralising antibodies 17.95 15.49 4 25530 55 90602858
Skin necrosis 17.95 15.49 23 25511 16918 90585995
Stress 17.85 15.49 57 25477 81338 90521575
COVID-19 17.73 15.49 13 25521 168830 90434083
Visual acuity reduced 17.66 15.49 27 25507 23383 90579530
Cognitive disorder 17.46 15.49 51 25483 69356 90533557
Central nervous system inflammation 17.46 15.49 5 25529 196 90602717
Cellulitis 17.41 15.49 61 25473 91276 90511637
Drug ineffective 16.80 15.49 282 25252 1384016 89218897
Limb mass 16.44 15.49 11 25523 3517 90599396
Extensor plantar response 16.33 15.49 8 25526 1419 90601494
Caesarean section 16.29 15.49 23 25511 18554 90584359
Musculoskeletal disorder 16.27 15.49 25 25509 21744 90581169
Asthma 16.23 15.49 27 25507 242133 90360780
Thrombocytopenia 16.21 15.49 21 25513 208704 90394209
Neuromyelitis optica spectrum disorder 16 15.49 8 25526 1482 90601431
Intervertebral disc protrusion 15.96 15.49 28 25506 27168 90575745
Dry mouth 15.92 15.49 17 25517 184042 90418871
Autoimmune hepatitis 15.89 15.49 17 25517 10334 90592579

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 553.33 24.22 170 7229 14094 42599842
Influenza like illness 472.19 24.22 185 7214 31655 42582281
Injection site pain 303.04 24.22 163 7236 57635 42556301
Injection site erythema 242.58 24.22 101 7298 20094 42593842
Injection site reaction 169.98 24.22 73 7326 15648 42598288
Multiple sclerosis 159.20 24.22 57 7342 7541 42606395
Injection site mass 148.83 24.22 56 7343 8519 42605417
Gait disturbance 136.11 24.22 122 7277 97878 42516058
Injection site cellulitis 125.88 24.22 28 7371 638 42613298
Chills 124.51 24.22 114 7285 93952 42519984
Injection site infection 111.26 24.22 28 7371 1098 42612838
Depression 84.11 24.22 100 7299 111263 42502673
Injection site abscess 84.04 24.22 22 7377 1010 42612926
Hypoaesthesia 81.83 24.22 80 7319 71383 42542553
Injection site induration 80.01 24.22 28 7371 3459 42610477
Gait inability 75.81 24.22 48 7351 22785 42591151
Injection site scar 69.14 24.22 16 7383 437 42613499
Expanded disability status scale score increased 63.83 24.22 15 7384 439 42613497
Balance disorder 63.40 24.22 58 7341 47587 42566349
Injection site rash 59.96 24.22 26 7373 5686 42608250
Muscular weakness 53.36 24.22 69 7330 83429 42530507
Mobility decreased 50.94 24.22 45 7354 35261 42578675
Injection site inflammation 50.32 24.22 15 7384 1111 42612825
Injection site necrosis 45.00 24.22 12 7387 592 42613344
Muscle spasticity 43.50 24.22 22 7377 6800 42607136
Injection site bruising 42.72 24.22 26 7373 11499 42602437
Optic neuritis 40.70 24.22 18 7381 4124 42609812
Injection site swelling 40.31 24.22 29 7370 16944 42596992
Depressed mood 40.27 24.22 33 7366 23351 42590585
Myopathy toxic 38.07 24.22 11 7388 730 42613206
Muscle spasms 33.06 24.22 56 7343 85988 42527948
Acute kidney injury 31.91 24.22 12 7387 367325 42246611
Injection site haematoma 31.32 24.22 12 7387 1913 42612023
Injection site discolouration 31.31 24.22 12 7387 1914 42612022
Hepatitis toxic 31.31 24.22 13 7386 2554 42611382
Skin necrosis 30.72 24.22 17 7382 6297 42607639
Headache 30.50 24.22 101 7298 239268 42374668
Secondary progressive multiple sclerosis 29.70 24.22 8 7391 410 42613526
Muscle disorder 29.09 24.22 13 7386 3051 42610885
Hemianaesthesia 28.86 24.22 6 7393 98 42613838
Visual impairment 28.09 24.22 36 7363 43077 42570859
Demyelination 27.34 24.22 13 7386 3516 42610420
Tremor 27.07 24.22 55 7344 96874 42517062
Product dose omission issue 26.10 24.22 72 7327 154293 42459643
Ischaemia 25.69 24.22 14 7385 5033 42608903
Pyrexia 24.80 24.22 134 7265 393908 42220028
Vision blurred 24.78 24.22 38 7361 53661 42560275

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1663.05 15.11 576 26251 49664 110512808
Influenza like illness 1119.29 15.11 506 26321 87906 110474566
Injection site erythema 977.87 15.11 470 26357 93706 110468766
Injection site pain 895.17 15.11 549 26278 177373 110385099
Injection site mass 491.44 15.11 195 26632 24418 110538054
Injection site reaction 478.24 15.11 287 26540 88783 110473689
Multiple sclerosis 418.70 15.11 176 26651 25522 110536950
Injection site bruising 360.31 15.11 197 26630 51066 110511406
Chills 338.97 15.11 316 26511 190264 110372208
Injection site induration 276.34 15.11 104 26723 11279 110551193
Injection site cellulitis 268.01 15.11 68 26759 1952 110560520
Gait disturbance 253.01 15.11 324 26503 277884 110284588
Injection site rash 248.92 15.11 119 26708 23300 110539172
Injection site necrosis 232.08 15.11 59 26768 1707 110560765
Injection site scar 215.40 15.11 51 26776 1089 110561383
Injection site abscess 205.56 15.11 55 26772 1951 110560521
Injection site infection 205.09 15.11 58 26769 2535 110559937
Depression 184.62 15.11 299 26528 317036 110245436
Injection site atrophy 180.62 15.11 38 26789 461 110562011
Product dose omission issue 180.18 15.11 298 26529 321484 110240988
Balance disorder 174.50 15.11 176 26651 116384 110446088
Hypoaesthesia 154.81 15.11 275 26552 313948 110248524
Injection site haematoma 132.12 15.11 49 26778 5097 110557375
Optic neuritis 128.74 15.11 60 26767 11087 110551385
Injection site discolouration 127.32 15.11 56 26771 9047 110553425
Injection site inflammation 117.27 15.11 44 26783 4727 110557745
Muscular weakness 116.60 15.11 213 26614 248255 110314217
Injection site swelling 114.54 15.11 105 26722 61685 110500787
Injection site ulcer 113.66 15.11 29 26798 851 110561621
Gait inability 104.07 15.11 146 26681 136230 110426242
Off label use 102.17 15.11 129 26698 1500056 109062416
Depressed mood 96.81 15.11 95 26732 60714 110501758
Tremor 84.45 15.11 165 26662 202067 110360405
Acute kidney injury 82.18 15.11 26 26801 635404 109927068
Infusion related reaction 79.33 15.11 3 26824 381159 110181313
Fall 75.64 15.11 318 26509 603164 109959308
Toxicity to various agents 75.26 15.11 13 26814 480542 110081930
Hemianaesthesia 63.19 15.11 16 26811 455 110562017
Central nervous system lesion 63.01 15.11 42 26785 15511 110546961
Drug interaction 61.96 15.11 22 26805 500161 110062311
Pyrexia 60.27 15.11 398 26429 897867 109664605
Secondary progressive multiple sclerosis 59.62 15.11 20 26807 1549 110560923
Coordination abnormal 59.09 15.11 49 26778 25179 110537293
Paraparesis 57.17 15.11 26 26801 4540 110557932
Expanded disability status scale score increased 56.93 15.11 17 26810 901 110561571
Pain in extremity 55.83 15.11 250 26577 486868 110075604
Feeling cold 55.77 15.11 54 26773 33933 110528539
Febrile neutropenia 55.64 15.11 6 26821 316761 110245711
Progressive multiple sclerosis 54.80 15.11 18 26809 1306 110561166
Injection site calcification 53.97 15.11 9 26818 25 110562447
Headache 53.84 15.11 382 26445 881995 109680477
Seizure 52.96 15.11 145 26682 221040 110341432
Urinary tract infection 50.58 15.11 184 26643 326098 110236374
Sensory disturbance 49.69 15.11 38 26789 17391 110545081
Injection site irritation 49.21 15.11 24 26803 4900 110557572
Joint swelling 49.11 15.11 23 26804 442822 110119650
Injection site urticaria 47.91 15.11 37 26790 17178 110545294
Neutropenia 47.19 15.11 16 26811 374604 110187868
Completed suicide 46.93 15.11 3 26824 242378 110320094
Muscle spasms 46.65 15.11 161 26666 277996 110284476
Urinary incontinence 46.25 15.11 58 26769 48529 110513943
Mobility decreased 44.78 15.11 143 26684 237279 110325193
Muscle spasticity 44.37 15.11 49 26778 35866 110526606
Lower respiratory tract infection 44.27 15.11 4 26823 243102 110319370
Injection site haemorrhage 44.19 15.11 47 26780 32981 110529491
Injection site pruritus 43.79 15.11 58 26769 51200 110511272
Diarrhoea 43.62 15.11 137 26690 1139368 109423104
Drug ineffective 43.36 15.11 206 26621 1520334 109042138
Wheezing 41.97 15.11 6 26821 255224 110307248
Demyelination 41.95 15.11 27 26800 9402 110553070
Fatigue 41.25 15.11 463 26364 1215495 109346977
Rheumatoid arthritis 40.98 15.11 11 26816 299602 110262870
Feeling abnormal 40.82 15.11 116 26711 180595 110381877
Decreased interest 40.47 15.11 21 26806 4887 110557585
Intentional product use issue 40.36 15.11 6 26821 247900 110314572
Abdominal discomfort 39.89 15.11 23 26804 393835 110168637
Hypotension 39.84 15.11 41 26786 523808 110038664
Vision blurred 39.65 15.11 93 26734 128929 110433543
Breast cancer female 39.59 15.11 29 26798 12439 110550033
Stomatitis 38.75 15.11 9 26818 270233 110292239
Limb discomfort 37.66 15.11 48 26779 40806 110521666
Glossodynia 37.02 15.11 5 26822 221999 110340473
Arthropathy 36.69 15.11 12 26815 287510 110274962
Asthenia 36.68 15.11 289 26538 688710 109873762
Injection site scab 35.92 15.11 11 26816 635 110561837
Rash 35.55 15.11 93 26734 820871 109741601
General physical health deterioration 34.99 15.11 31 26796 425264 110137208
Pain 34.80 15.11 369 26458 954586 109607886
Thrombocytopenia 34.44 15.11 21 26806 348864 110213608
Loss of consciousness 34.10 15.11 115 26712 196191 110366281
Visual impairment 34.04 15.11 90 26737 134338 110428134
Psoriatic arthropathy 33.85 15.11 4 26823 196757 110365715
Muscle tightness 33.18 15.11 28 26799 14734 110547738
Skin necrosis 33.10 15.11 33 26794 21479 110540993
Overdose 33.09 15.11 8 26819 233786 110328686
Injection site nodule 33.01 15.11 18 26809 4628 110557844
Speech disorder 32.98 15.11 56 26771 61513 110500959
Magnetic resonance imaging abnormal 32.87 15.11 17 26810 3928 110558544
Oedema 32.14 15.11 6 26821 209970 110352502
Hyponatraemia 31.69 15.11 7 26820 217646 110344826
Paraesthesia 31.68 15.11 142 26685 276379 110286093
Therapeutic product effect decreased 31.52 15.11 10 26817 244306 110318166
Wound 31.32 15.11 9 26818 234428 110328044
Anti-interferon antibody positive 30.81 15.11 5 26822 11 110562461
Burning sensation 30.72 15.11 58 26769 69154 110493318
Hemiparesis 30.52 15.11 45 26782 43858 110518614
Memory impairment 30.43 15.11 111 26716 196833 110365639
C-reactive protein increased 29.80 15.11 8 26819 217911 110344561
Product use in unapproved indication 29.70 15.11 39 26788 447338 110115134
Diplopia 29.21 15.11 43 26784 41851 110520621
Osteoarthritis 28.42 15.11 5 26822 182618 110379854
Musculoskeletal disorder 28.13 15.11 31 26796 22633 110539839
Monoparesis 27.88 15.11 16 26811 4537 110557935
Fat necrosis 27.81 15.11 10 26817 952 110561520
Neutralising antibodies positive 27.64 15.11 8 26819 380 110562092
Condition aggravated 27.59 15.11 89 26738 734747 109827725
Therapeutic product effect incomplete 27.41 15.11 10 26817 223795 110338677
Ataxia 27.16 15.11 35 26792 30073 110532399
Systemic lupus erythematosus 26.98 15.11 14 26813 254324 110308148
Injection site injury 26.47 15.11 10 26817 1094 110561378
Blister 26.46 15.11 11 26816 227365 110335107
Drug intolerance 26.41 15.11 36 26791 406476 110155996
Trigeminal neuralgia 25.87 15.11 15 26812 4337 110558135
Treatment failure 25.57 15.11 18 26809 277216 110285256
Peroneal nerve palsy 25.27 15.11 18 26809 7396 110555076
Ill-defined disorder 25.06 15.11 4 26823 156849 110405623
Gastrointestinal disorder 24.67 15.11 14 26813 241938 110320534
Bronchopulmonary aspergillosis 24.30 15.11 33 26794 29830 110532642
Injection site fibrosis 24.29 15.11 4 26823 10 110562462
Pneumonia 24.16 15.11 120 26707 876594 109685878
Fibromyalgia 23.89 15.11 6 26821 170903 110391569
Weight increased 23.58 15.11 41 26786 419603 110142869
Neuromyelitis optica spectrum disorder 23.41 15.11 10 26817 1505 110560967
Panniculitis lobular 23.37 15.11 5 26822 66 110562406
Ophthalmoplegia 23.15 15.11 13 26814 3537 110558935
Band sensation 23.11 15.11 9 26818 1069 110561403
Pancytopenia 23.04 15.11 11 26816 209602 110352870
Hyperkalaemia 22.77 15.11 3 26824 135793 110426679
Decubitus ulcer 22.73 15.11 25 26802 18211 110544261
Scar 22.54 15.11 24 26803 16857 110545615
Irritable bowel syndrome 22.50 15.11 6 26821 164209 110398263
Intentional overdose 22.04 15.11 3 26824 132498 110429974
Connective tissue inflammation 21.97 15.11 3 26824 0 110562472
Injection site nerve damage 21.57 15.11 5 26822 97 110562375
Liver injury 21.57 15.11 5 26822 150408 110412064
Type 2 diabetes mellitus 21.56 15.11 8 26819 177224 110385248
Bursitis 21.48 15.11 3 26824 129915 110432557
Anaemia 21.40 15.11 65 26762 547021 110015451
Myopathy toxic 21.31 15.11 9 26818 1316 110561156
Cellulitis 21.15 15.11 73 26754 125943 110436529
Thyroid function test abnormal 21.07 15.11 12 26815 3355 110559117
Visual acuity reduced 20.97 15.11 32 26795 32141 110530331
Caesarean section 20.89 15.11 21 26806 13796 110548676
Bladder disorder 20.77 15.11 19 26808 11118 110551354
Magnetic resonance imaging head abnormal 20.52 15.11 12 26815 3523 110558949
Peripheral swelling 20.48 15.11 42 26785 403992 110158480
Head injury 20.28 15.11 37 26790 42980 110519492
Injection site warmth 20.22 15.11 23 26804 17382 110545090
COVID-19 19.97 15.11 18 26809 245042 110317430
Injury 19.95 15.11 9 26818 177256 110385216
Ischaemia 19.94 15.11 17 26810 9066 110553406
Motor dysfunction 19.90 15.11 27 26800 24379 110538093
Lipoatrophy 19.88 15.11 7 26820 627 110561845
Decreased appetite 19.73 15.11 55 26772 475791 110086681
Dyspnoea 19.63 15.11 173 26654 1106699 109455773
Neutrophil count decreased 19.51 15.11 3 26824 120938 110441534
Diplegia 19.50 15.11 10 26817 2271 110560201
Drug hypersensitivity 19.18 15.11 52 26775 454038 110108434
Lack of injection site rotation 19.02 15.11 8 26819 1158 110561314
Progressive relapsing multiple sclerosis 18.90 15.11 4 26823 50 110562422
Dizziness 18.85 15.11 255 26572 697938 109864534
Thyroid neoplasm 18.62 15.11 11 26816 3290 110559182
Injection site erosion 18.56 15.11 5 26822 182 110562290
Micturition urgency 18.28 15.11 23 26804 19297 110543175
Skin discolouration 18.04 15.11 38 26789 49008 110513464
Muscle disorder 17.83 15.11 14 26813 6658 110555814
Skin warm 17.80 15.11 16 26811 9154 110553318
Joint range of motion decreased 17.57 15.11 4 26823 121828 110440644
Accident at home 17.45 15.11 5 26822 229 110562243
Hyperreflexia 17.33 15.11 16 26811 9469 110553003
Migraine 17.33 15.11 85 26742 171567 110390905
Automatic bladder 17.28 15.11 4 26823 77 110562395
Hepatitis toxic 17.08 15.11 13 26814 5908 110556564
Blood creatinine increased 16.69 15.11 12 26815 182877 110379595
JC polyomavirus test positive 16.42 15.11 9 26818 2338 110560134
Renal impairment 16.39 15.11 13 26814 188432 110374040
Dysstasia 16.35 15.11 29 26798 32957 110529515
Incontinence 16.05 15.11 20 26807 16615 110545857
Interstitial lung disease 15.79 15.11 7 26820 139327 110423145
Panniculitis 15.46 15.11 19 26808 15563 110546909
Decreased vibratory sense 15.40 15.11 6 26821 714 110561758
Impaired healing 15.38 15.11 15 26812 196702 110365770
Nervousness 15.27 15.11 30 26797 36821 110525651
Central nervous system inflammation 15.26 15.11 5 26822 360 110562112
Eye pain 15.26 15.11 36 26791 50063 110512409

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AB08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
FDA CS M0025715 Interferon-beta
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D007155 Immunologic Factors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:64946 anti-HIV agent
FDA EPC N0000191625 Interferon beta

Related Drugs by ATC class:

L03AB Interferons 6 drugs
interferon alfa-2binterferon beta-1apeginterferon alfa-2apeginterferon alfa-2bpeginterferon beta-1aropeginterferon alfa-2b

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interferon alpha/beta receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
TTD90R31WZ UNII
4023900 VANDF
C0244713 UMLSCUI
CHEBI:5938 CHEBI
CHEMBL1201563 ChEMBL_ID
D00746 KEGG_DRUG
DB00068 DRUGBANK_ID
D000068576 MESH_DESCRIPTOR_UI
72257 RXNORM
304 MMSL
4896 MMSL
d03051 MMSL
004370 NDDF
108751004 SNOMEDCT_US
386903009 SNOMEDCT_US

Pharmaceutical products:

None